Literature DB >> 21039475

Inhibition of neutrophil migration in mice by mouse formyl peptide receptors 1 and 2 dual agonist: indication of cross-desensitization in vivo.

Yoshitaka Sogawa1, Takao Ohyama, Hiroaki Maeda, Kazuki Hirahara.   

Abstract

It has been reported that the stimulation of neutrophils with N-formyl-Met-Leu-Phe (fMLF), an agonist for formyl peptide receptor (Fpr) 1, renders cells unresponsive to other chemoattractants in vitro. This is known as cross-desensitization, but its functional relevance in neutrophil migration in vivo has not been investigated. Here, we show that precedent stimulation of mouse neutrophils with compound 43, a non-peptidyl agonist for mouse Fpr1 and Fpr2, rendered the cells unresponsive to a second stimulation with C5a, leukotriene B₄, or keratinocyte-derived cytokine (KC) in calcium mobilization and chemotaxis assays in vitro. The expression of chemokine (C-X-C motif) receptor 2 (CXCR2) on the surface of neutrophils was concomitantly diminished by stimulating the cells with the compound. Moreover, oral administration of the compound to mice before they were exposed to lipopolysaccharide (LPS) aerosol resulted in a dose-dependent reduction in the neutrophil count in bronchoalveolar lavage fluid. The expression of CXCR2 on blood neutrophils was also reduced in the compound-administered mice. The recipient mice that underwent adoptive transfer of fluorescence-labelled neutrophils that had been incubated with the compound showed a substantial decrease in neutrophil counts in bronchoalveolar lavage fluid after they were exposed to LPS, when compared with the control mice to which vehicle-treated neutrophils had been transferred. These results are consistent with the idea that the agonist for Fpr1 and Fpr2 induced cross-desensitization in neutrophils and attenuated neutrophil migration into the airways. Our results also revealed the unpredicted effect of an Fpr1 and Fpr2 dual agonist, which may act as a functional antagonist for multiple chemoattractant receptors in vivo.
© 2010 The Authors. Immunology © 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21039475      PMCID: PMC3044910          DOI: 10.1111/j.1365-2567.2010.03367.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  46 in total

1.  The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment.

Authors:  Q Ma; D Jones; T A Springer
Journal:  Immunity       Date:  1999-04       Impact factor: 31.745

2.  A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R.

Authors:  X Deng; H Ueda; S B Su; W Gong; N M Dunlop; J L Gao; P M Murphy; J M Wang
Journal:  Blood       Date:  1999-08-15       Impact factor: 22.113

3.  Differential expansion of the N-formylpeptide receptor gene cluster in human and mouse.

Authors:  J L Gao; H Chen; J D Filie; C A Kozak; P M Murphy
Journal:  Genomics       Date:  1998-07-15       Impact factor: 5.736

Review 4.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

Review 5.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

6.  The pyrazolone originally reported to be a formyl peptide receptor (FPR) 2/ALX-selective agonist is instead an FPR1 and FPR2/ALX dual agonist.

Authors:  Yoshitaka Sogawa; Akiko Shimizugawa; Takao Ohyama; Hiroaki Maeda; Kazuki Hirahara
Journal:  J Pharmacol Sci       Date:  2009-11       Impact factor: 3.337

7.  Neutrophil influx into the lungs of beige mice is followed by elastolytic damage and emphysema.

Authors:  E Cavarra; P A Martorana; M de Santi; B Bartalesi; S Cortese; F Gambelli; G Lungarella
Journal:  Am J Respir Cell Mol Biol       Date:  1999-02       Impact factor: 6.914

8.  Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit.

Authors:  Charles G Lo; Ying Xu; Richard L Proia; Jason G Cyster
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

9.  N-formylpeptides induce two distinct concentration optima for mouse neutrophil chemotaxis by differential interaction with two N-formylpeptide receptor (FPR) subtypes. Molecular characterization of FPR2, a second mouse neutrophil FPR.

Authors:  J K Hartt; G Barish; P M Murphy; J L Gao
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

10.  Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor.

Authors:  J L Gao; E J Lee; P M Murphy
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307

View more
  9 in total

Review 1.  Peeking into the secret life of neutrophils.

Authors:  Jackson LiangYao Li; Lai Guan Ng
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 2.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

3.  Pyridazinones and Structurally Related Derivatives with Anti-Inflammatory Activity.

Authors:  Niccolo Cantini; Igor A Schepetkin; Nadezhda V Danilenko; Andrei I Khlebnikov; Letizia Crocetti; Maria Paola Giovannoni; Liliya N Kirpotina; Mark T Quinn
Journal:  Molecules       Date:  2022-06-10       Impact factor: 4.927

4.  Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity.

Authors:  Jennifer H Madenspacher; Kathleen M Azzam; Wanghua Gong; Kymberly M Gowdy; Michael P Vitek; Daniel T Laskowitz; Alan T Remaley; Ji Ming Wang; Michael B Fessler
Journal:  J Biol Chem       Date:  2012-11-01       Impact factor: 5.157

5.  A formyl peptide receptor agonist suppresses inflammation and bone damage in arthritis.

Authors:  W Kao; R Gu; Y Jia; Xuemin Wei; H Fan; J Harris; Zhiyi Zhang; J Quinn; E F Morand; Y H Yang
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

Review 6.  Resolution of chronic inflammatory disease: universal and tissue-specific concepts.

Authors:  Georg Schett; Markus F Neurath
Journal:  Nat Commun       Date:  2018-08-15       Impact factor: 14.919

7.  Formyl Peptide Receptor 2 Activation Ameliorates Dermal Fibrosis and Inflammation in Bleomycin-Induced Scleroderma.

Authors:  Gyu Tae Park; Yang Woo Kwon; Tae Wook Lee; Seong Gyu Kwon; Hyun-Chang Ko; Moon Bum Kim; Jae Ho Kim
Journal:  Front Immunol       Date:  2019-09-03       Impact factor: 7.561

Review 8.  International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Authors:  Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik
Journal:  Pharmacol Rev       Date:  2013-11-11       Impact factor: 25.468

Review 9.  Neutrophil chemoattractant receptors in health and disease: double-edged swords.

Authors:  Mieke Metzemaekers; Mieke Gouwy; Paul Proost
Journal:  Cell Mol Immunol       Date:  2020-04-01       Impact factor: 11.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.